Vaccines (ISSN 2076-393X) has had a five-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

- **Open Access** Unlimited and free access for readers
- **No Copyright Constraints** Retain copyright of your work and free use of your article
- **Thorough Peer-Review**
- **2021 Impact Factor: 4.961** *(Journal Citation Reports - Clarivate, 2022)*
- **Discounts on Article Processing Charges (APC)** If you belong to an institute that participates with the MDPI Institutional Open Access Program
- **No Space Constraints, No Extra Space or Color Charges** No restriction on the length of the papers, number of figures or colors
- **Coverage by Leading Indexing Services** Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases
- **Rapid Publication** First decision provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2022)
Aims and Scope

Vaccines is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. It publishes reviews, research articles, case reports, etc. There is no restriction on the length of papers. We encourage scientists to publish the results in as much detail as possible.

The scope of Vaccines includes:

- Immunology mechanisms
- Animal models for immunologic diseases
- Viral immunology
- Immunopathogenesis
- Vaccine development and efficacy evaluation
- Immune responses to vaccines
- Vaccine technology
- Vaccine vectors, adjuvants and immunomodulators
- Prophylactic vaccines, therapeutic vaccines, AIDS vaccines, gene vaccines, vaccines in bioterrorism
- Regulatory affairs, commercial utilization, policy, safety

Sections

- Vaccines against Infectious Diseases
- Therapeutic Vaccines and Antibody Therapeutics
- Cancer Vaccines and Immunotherapy
- Influenza Virus Vaccines
- HIV Vaccines
- Veterinary Vaccines
- Vaccines against (re)emerging and Tropical Infectious Diseases
- Epidemiology
- Toxicology Studies and Clinical Trials
- Immune Mechanisms
- Vaccines and Society
- Failed Vaccines and Vaccine Antigens
- Vaccine Adjuvants
- Attenuated/Inactivated/Live and Vectored Vaccines
- Clinical Immunology
- Cellular/Molecular Immunology
- Pathogens-host Immune Interface
- Human Papillomavirus Vaccines
- Hepatitis Virus Vaccines
- COVID-19 Vaccines and Vaccination
- General

Editorial Office

Vaccines Editorial Office
vaccines@mdpi.com
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
www.mdpi.com
mdpi.com/journal/vaccines